

5,10,15,20-Tetrakis(4-sulfonatophenyl)porphyrin Zinc and Chloro-aluminum Phthalocyanine Disulfonate in Photodynamic Therapy of Colorectal Adenocarcinoma *In Vitro*

JAKUB HOSIK, BARBORA HOSIKOVA, HANA KOLAROVA and ROBERT BAJGAR

*Department of Medical Biophysics, Faculty of Medicine and Dentistry,
Palacky University in Olomouc, Olomouc, Czech Republic*

Abstract. *Background/Aim:* Colorectal cancer (CRC) is one of the most widespread malignancies. One of the alternative therapeutic methods appears to be photodynamic therapy (PDT). *Materials and Methods:* This study investigated the efficiency of 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin zinc (ZnTPPS₄) and chloro-aluminum phthalocyanine disulfonate (ClAlPcS₂) with two commercial photosensitive compounds 5,10,15,20-tetrakis(1-methylpyridinium-4-yl)porphyrin (TMPyP) and tetramethylthionine chloride (methylene blue, MB) in PDT for CRC *in vitro*. In addition to the study of the photodynamic effect on the viability of the colorectal carcinoma cell line HT29, cellular uptake, ROS production, and DNA damage were investigated. *Results:* All photosensitizers showed good accumulation within HT29 cells, high efficiency in killing the cells, and a concentration-dependent increase in the production of ROS. *Conclusion:* PDT using ZnTPPS₄ and ClAlPcS₂ may be effective in the treatment of CRC, achieving a similar photocytotoxic effect at much lower concentrations compared to MB.

The increasing prevalence of cancer has prompted scientists and clinicians from various fields to explore new, safer, and more potent treatment options. Colorectal cancer (CRC) is one of the most widespread malignancies and ranks as the second leading cause of tumor-related deaths in women and the third most common in men worldwide (1). Moreover, it has been predicted that the incidence and mortality rate of CRC will

increase by 60% by 2030 (2). Despite progressions in science and medicine, a third of patients diagnosed with CRC have metastases, and cancer recurrence occurs in every second patient, even after radical treatment. The most common treatments for CRC include surgery, chemotherapy, radiotherapy, and immunotherapy, with their effectiveness highly dependent on tumor size, stage, and advancement of cancer. Surgery is the most widely used treatment modality. It is based on excising the lesion and is mostly effective during the early stages of colorectal carcinoma. However, during the procedure, tumor cells may spread into the circulatory system, or some tumor parts may remain unresected.

One of the alternative therapeutic methods appears to be photodynamic therapy (PDT). PDT is a non-invasive method that uses light to destroy tumors. After applying a photoactive compound (photosensitizer) and exposing it to visible light, a photodynamic reaction occurs that produces reactive oxygen species (ROS) (3). ROS harm biomolecules, such as lipids, proteins, and nucleic acids, leading to cell death and tumor eradication. In addition, the photosensitizer tends to concentrate in tumor cells, resulting in fewer side effects. Although this minimally invasive approach can have many of the above-mentioned benefits, it is still not as widely used.

One of the major research interests in PDT is the development of selective photosensitizers that accumulate preferentially in malignant tissue compared to normal tissue. Photosensitizers used in PDT represent diverse groups of chemical compounds including porphyrins, chlorophylls, bacteriochlorines, phthalocyanines, pheoforbides, purpurines, 5-aminolevulinic acid (ALA), texaphirines, *etc.* (4). Their efficacy in photosensitization reflects their physicochemical properties, light-absorption characteristics and yield of the photodynamic reaction *via* electron transitions and energy transfer to oxygen molecule. In addition, pharmacokinetic and pharmacodynamic properties as well as the microenvironment must be included in a supposed photoanticancer profile. Over the last three decades, a large number of porphyrin- and phthalocyanine-based photosensitizers have been synthesized

Correspondence to: Robert Bajgar (ORCID 0000-0003-4854-4114), Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 3, 775 15 Olomouc, Czech Republic. E-mail: robert.bajgar@upol.cz

Key Words: Colorectal adenocarcinoma, DNA fragmentation, photodynamic therapy, phthalocyanines, porphyrins, reactive oxygen species.

and evaluated for their photodynamic activity. Porphyrins are cyclic organic compounds, composed of four pyrrole units linked by four methine bridges (5). Their characteristics include a high absorption of light in the Soret region and an increased production of singlet oxygen and free radicals (6). However, their major drawback, apart from their lipophilicity, is poor tumor specificity and long-term sensitivity of the skin to light (7). Phthalocyanines are larger aromatic compounds consisting of four isoindole units connected by a ring of nitrogen atoms. Their absorption spectrum is in the red region (630-700 nm) thereby enabling a better penetration into the tissue. They cause minimal skin phototoxicity and exhibit significant cytotoxic activity against most tumor cells (8). To improve the phototherapeutic potential of the porphyrin- and phthalocyanine-based photosensitizers, researchers have developed diverse methods to chemically modify and functionalize these compounds, *e.g.* by triazines, polyethylene glycol, coordination with metal atoms (9) or their incorporation in nanostructures (4).

The goal of our presented study was to investigate the difference in the efficiency of four different water-soluble photosensitizers (Figure 1), 5,10,15,20-tetrakis(1-methylpyridinium-4-yl)porphyrin (TMPyP), 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin zinc (ZnTPPS₄), tetramethylthionine chloride (methylene blue, MB), and chloro-aluminum phthalocyanine disulfonate (CIAIPcS₂), in the PDT of the human colorectal adenocarcinoma cells HT29.

Materials and Methods

Cell line, photosensitizers, cultivation, and irradiation conditions. Colorectal carcinoma cell line HT29 (ATCC, Manassas, VA, USA) was grown in Dulbecco's modified Eagle's medium (DMEM) (Merck, Darmstadt, Germany) supplemented with fetal bovine serum (10% v/v, Biowest, Nuaille, France), penicillin and streptomycin solution (100 U/ml and 100 µg/ml, respectively, Merck), and photosensitizers in 96-well microplates (10,000 cells/well), in darkness and under a humidified atmosphere with 5% CO₂ at 37°C. TMPyP and MB were purchased from Merck (Merck), whereas ZnTPPS₄ and CIAIPcS₂ were synthesized and donated by Jiří Mosinger (Department of Inorganic Chemistry, Charles University in Prague, Czech Republic) and Jan Rakušan (Centre for Organic Chemistry Ltd, Rybitví, Czech Republic), respectively. Their synthesis was described previously (10, 11). The chemical structures of these photosensitizers are shown in Figure 1.

Two LED light sources providing emission maxima at 415 nm (full width at half maximum (FWHM) 20 nm) and 634 nm (FWHM 20 nm) were used for cell irradiation. The light sources were specifically designed for the experimental microplate irradiation and are protected by the National Patent CZ302829B6. Cells treated with TMPyP and ZnTPPS₄ were exposed to the 415 nm source at 38 mW/cm² whereas those treated with MB and CIAIPcS₂ to the 634 nm source at 45 mW/cm² at total irradiation doses of 2.5, 5, and 10 J/cm².

Fluorescence microscopy. The intracellular distribution of photosensitizers at the initial concentration of 10 µM after 24 h of

incubation was visualized using the inverted fluorescence microscope Olympus IX 70 equipped with a CCD camera (Olympus, Tokyo, Japan) and the Olympus imaging software CellM and CellR (Olympus Soft Imaging Solutions, Planegg, Germany) were used for analysis. Before fluorescence microscopy, the extracellular medium was properly replaced with fresh PBS buffer.

Viability measurement. The cytotoxic and phototoxic effect of photosensitizers was evaluated using the MTT viability test (MERCK). After incubation of HT29 cells with photosensitizer, irradiation in PBS, and another 24 h of incubation in the fresh DMEM, an aliquot of MTT solution was added, so that the final concentration of MTT was 0.5 mg/ml. After 3 h, the medium was removed, and the resulting formazan product was dissolved in dimethyl sulfoxide and quantified by measurement of absorbance at 570 nm.

Estimation of ROS. After 24 h of cell incubation with photosensitizer, DMEM was replaced with PBS, fluorescence probe 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (CM-H2DCFDA, Thermo Fisher Scientific, Invitrogen, Carlsbad, CA, USA) was added at the final concentration of 10 µM and left incubated for 20 min in the dark. After PDT, the fluorescence of CM-DCF within sensitized cells (excitation and emission wavelength was 480 nm and 530 nm, respectively) was recorded using the multi-reader Tecan Infinite 200pro (Tecan Group, Männedorf, Switzerland).

Comet assay – DNA fragmentation analysis. After irradiation with a dose of 5 J/cm², PBS was replaced with the DMEM, and the cell line HT29 was incubated for 6 or 24 h. Microscope slides were precoated with 1% high melting point (HMP) agarose (SERVA Electrophoresis, Heidelberg, Germany) dissolved in distilled water and placed in a drying oven for 30 min at a temperature of 60°C. Then an aliquot of 1% HMP agarose was also applied on the precoated slides, covered with a coverslip, and placed in a refrigerator for agarose gelling enhancement. The cells were detached from the wells using TrypLe solution (TrypLe, Thermo Fisher Scientific, Gibco, Grand Island, NY, USA). The cell suspensions were centrifuged for 4 min at 300 × g. Pellets were then dispersed in 20 µl of PBS and vortexed. After the addition of 80 µl of 1% low melting point (LMP) agarose (Merck), the suspensions were placed on the solidified agarose on the precoated microscope slide, covered with the original coverslips and transferred to a refrigerator for 15 min. After solidifying, the samples were immersed in a lysis buffer (2.5 M NaCl, 100 mM EDTA (ethylenediaminetetraacetic acid), 10 mM Tris [tris(hydroxymethyl)aminomethane], 1% Triton X-100, pH 10) at 4°C for 60 min. After the lysis, the slides were placed in an electrophoretic tank and dipped in a cool electrophoretic solution (300 mM NaOH, 1 mM EDTA) for 40 min. The electrophoresis was run at 350 mA and 0.8 V/cm for 20 min. After the electrophoretic separation, the slides were carefully rinsed twice for 10 min with a neutralization buffer (0.4 M Tris, pH 7.5) at 4°C, stained using SYBR Green (Merck), and visualized using a fluorescence microscope with CCD camera. Finally, the cell DNA was manually scored using CometScore 1.5 software (TriTek, Corp., Sumerduck, VA, USA). For evaluation, we randomly chose 100 cells from each given sample. Median values of the amount of the DNA in the tail, which is directly proportional to the DNA damage, were evaluated.




Figure 1. Chemical structure of photosensitizers: (A) 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin zinc (ZnTPPS₄); (B) 5,10,15,20-tetrakis(1-methylpyridinium-4-yl)porphyrin (TMPyP); (C) chloro-aluminum phthalocyanine disulfonate (ClAlPcS₂); (D) tetramethylthionine chloride (methylene blue, MB).

Statistical analysis. The data are shown as means±standard errors for all measurements except the Comet assay, where the evaluating parameters correspond to the medians±standard errors. IC₅₀ values and Hill coefficients (h) were determined from three independent experiments by non-linear regression fits to sigmoidal curves using ORIGIN 6.0 software (OriginLab, Corp., Northampton, MA, USA). One-way analysis of variance (ANOVA) was used for comparisons between experimental groups. A *p*-value of <0.05 was considered statistically significant.

Results

Fluorescence microscopy. Cellular localization of all studied photosensitizers in HT29 cells after 24 h of incubation shows inhomogeneous distribution creating several small clusters within the cells (red fluorescence, Figure 2). The sites with significantly less accumulation were the nuclear regions.

Determination of the cell viability. The phototoxic effect of photosensitizers was investigated in HT29 cells 24 h after the application of PDT. Results showed (Figure 3) that the

cell viability was significantly influenced in concentration-dependent manners. The lowest IC₅₀ value was found for TMPyP-mediated PDT. MB turned out to be the least potent phototoxic compound. Here, the potency was more than 57 times lower compared to TMPyP-PDT. All the analyzed photosensitizers did not show a significant viability reduction when no light was applied (Figure 4), thus they all meet the basic criterion of ideal photosensitizer.

ROS production measurement. The increase in ROS production in HT29 cells was observed immediately after PDT using the fluorescent probe CM-H2DCFDA. All photosensitizers tested caused the increase in ROS production (Figure 5). Higher values in fluorescence intensities were achieved when using light with a wavelength of 415 nm, which the photooxidation of the fluorescent probe itself can cause.

DNA fragmentation analysis using Comet assay. The effect of the photosensitizers at the concentration of IC₅₀ and




Figure 2. Microscope images of live HT29 cells in transmission and fluorescence mode at an original image magnification of 400 times. The cells were incubated with: (A) ZnTPPS₄; (B) TMPyP; (C) ClAlPcS₂; (D) MB.

irradiation dose of 5 J/cm² on DNA double-strand break formation was evaluated using the Comet assay. Significant DNA fragmentation was observed after 24 h from PDT and only when MB was applied. Other photosensitizers caused minimal DNA damage similar to non-treated cells. The results are stated in Table I.

Discussion

Our study aimed at comparing the effectiveness four different photosensitizers, ZnTPPS₄, TMPyP, ClAlPcS₂, and MB, against CRC *in vitro*. Although all photosensitizers showed good efficacy in the PDT of HT29 cells, significantly lower IC₅₀ value was found for tetracationic TmPyP (0.47 μM). The highest IC₅₀ value at the same irradiation dose was obtained for MB (27 μM).

Nyman and Hynninen reported that the formation of a complex with a diamagnetic cation, for example with Al³⁺, Zn²⁺ and Ga³⁺, increases the yield and lifetime of the triplet state (12) and therefore the production of singlet oxygen and the subsequent oxidation of neighboring molecules can be supported. The comparison of ZnTPPS₄ with the commercially available TMPyP showed that the production of singlet oxygen was higher in the case of the non-zinc complex. This can be explained by the fact that we used a

source with an emission at 415/20 (maximum/FWHM) nm to induce the PDT, but the excitation peaks for TMPyP and ZnTPPS₄ are at 420/20 nm and 418/55 nm, respectively. The formation of ROS by ClAlPcS₂ and MB, both activated by red light (634/20 nm), and the dependence on concentration and irradiation dose is similar except for the highest used concentration (6 μM) and irradiation dose (10 J/cm²). Because the IC₅₀ value was more than 10 times lower for ClAlPcS₂, a difference in their cell target structures can be considered.

It is known that the uptake and localization of the photosensitizer in the target cells are influenced by the hydrophilic-lipophilic balance (13, 14). After incubation of HT29 cells with ZnTPPS₄, TMPyP, ClAlPcS₂, and MB, fluorescence microscopy revealed a high intracellular fluorescence, indicating that there was a substantial uptake of the photosensitizers into the cells. Although this method does not show a significant accumulation of the studied hydrophilic photosensitizers in the cell nucleus, the comet analysis showed that MB significantly damages DNA 24 h after PDT. MB is a positively charged molecule that binds to numerous cancer cells probably due to their hyperpolarized resting membrane potential in comparison to normal cells (15). In addition, the mitochondrial membrane in tumor cells also exhibits hyperpolarization, and therefore cationic photosensitizers may target this organelle (16). Thus, cell




Figure 3. The dependence of HT29 cell viability on photosensitizer concentration: (A) ZnTPPS₄; (B) TMPyP; (C) ClAlPcS₂; (D) MB. The dependence was determined by measuring the enzyme activity of living cells using the methylthiazol tetrazolium bromide test. The controls are represented by irradiated cells in the absence of photosensitizers and these values were set as 100%. Each data point is expressed as the mean $\pm$ SD of three independent measurements.

death by MB-PDT can be caused *via* apoptosis induced through mitochondria damage and subsequent activation of caspase 3 (17, 18) followed by late DNA fragmentation. However, MB also accumulates in lysosomes (17), induces high production of ROS, and is effective in the breast adenocarcinoma cell line MCF-7 (17, 19, 20) lacking expression of caspase 3. Therefore, the phototoxic effects of MB-PDT appear to be nonspecific, resulting in apoptosis, necrosis, necroptosis, and autophagy. It should also be mentioned that the type of cell death is significantly affected not only the type and concentration of the photosensitizer, but also other factors, including the cell genotype, oxygen level, and irradiation conditions (wavelength, fluence rate and exposure time) (21). In the case of the second cationic sensitizer, TMPyP, it was found that in addition to mitochondria and Golgi complex (22), it can accumulate in the cell nucleus of tumor cells, especially at a higher concentration or prolonged incubation time (23). However,




Figure 4. Dark cytotoxicity measurement of photosensitizers on HT29 cells. The cells were incubated with ZnTPPS₄, TMPyP, ClAlPcS₂, or MB. The controls are represented by the non-irradiated cells in the absence of photosensitizers and these values were set as 100%.




Figure 5. The dependence of ROS production in HT29 cells on the concentration of: (A) ZnTPPS₄; (B) TMPyP; (C) ClAlPcS₂; (D) MB and irradiation dose. Data are expressed as the mean±SD of three independent measurements.

our results showed that TMPyP-PDT did not lead to DNA fragmentation in HT29 cells. A similar finding in HeLa cells (cervical carcinoma) has been reported previously by Acedo *et al.* (21) who showed DNA fragmentation by TMPyP only in combination with zinc phthalocyanine. Surprisingly, the anionic photosensitizer ZnTPPS₄ also shows a certain affinity to mitochondria, because it induces changes in the mitochondrial membrane potential in HeLa and G361 (melanoma) cells in a concentration-dependent manner as was shown in one of our previous articles (24). Furthermore, it seems that TMPyP-PDT produces significant DNA fragmentation only at high doses (26 J/cm²) (25), which also confirms our observation in HT29 cells exposed to the relatively low dose of 5 J/cm². The second generation of photosensitizers, such as phthalocyanines, chlorins, and purpurins, absorb light in the red region and therefore allow better tissue penetration. However, their disadvantage is poor solubility in water. Sulfonation can be a solution to increase

Table I. DNA fragmentation after PDT using different photosensitizers at the IC₅₀ concentration and irradiation dose of 5 J/cm². Control represents non-irradiated cells in the absence of photosensitizer.

	DNA fragmentation [%]	
	6 h after PDT	24 h after PDT
ZnTPPS ₄	0.01±0.00	0.01±0.01
TMPyP	0.07±0.12	0.36±0.52
ClAlPcS ₂	0.81±1.41	2.16±3.73
MB	0.03±0.04	40.42±6.52
Control	0.86±0.64	0.01±0.00

PDT: Photodynamic therapy.

their tissue distribution as the formation of a complex with metal elements increases the yield and lifetime of the photosensitizer's triplet state as well as their ability to

produce ROS (12). We found that to induce the same lethality in HT29 cells, about 10 times less concentration of ClAlPcS₂ is needed compared to MB. Similar to TMPyP and ZnTPPS₄, ClAlPcS₂ did not lead to DNA cleavage. ClAlPcS₂ was also effective in HeLa cells, where its mechanism of action was related to the mitochondria causing damage to the respiratory chain, as we showed earlier (26).

Conclusion

Conventional diagnosis and treatment methods for CRC have limitations, including severe side effects, invasiveness, and the inability to treat late-stage CRC effectively. Current screening tests, both invasive and noninvasive, lack sensitivity to detect early-stage CRC. Therefore, researchers have been investigating diagnostic and therapeutic alternatives, such as PDT. The advantage of PDT in the treatment of CRC over conventional methods is its ability to specifically target and treat cancer cells without damaging surrounding tissues. This approach using light colonoscopy allows selective multiple dosage administration with negligible side effects. As our *in vitro* study shows, PDT using sulfonated porphyrin- and phthalocyanine-based photosensitizers coordinated with metal atoms such as ZnTPPS₄ and ClAlPcS₂ can be effective in the treatment of CRC.

Conflicts of Interest

All Authors declare that they have no competing interests in relation to this study.

Authors' Contributions

Jakub Hosik, Barbora Hosikova, and Robert Bajgar performed the experiments, analyzed the data, interpreted the results, and wrote the manuscript. Hana Kolarova provided assistance in editing the final version of the manuscript. All Authors reviewed the manuscript.

Funding

This study was supported by the Ministry of Health of the Czech Republic – grant projects NU21J-03-00062 and NU21-09-00357.

References

- World Cancer Research Fund International: Colorectal cancer statistics. Available at: <https://www.wcrf.org/cancer-trends/colorectal-cancer-statistics> [Last accessed on May 7, 2024]
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: Cancer Incidence and Mortality Worldwide. IARC Cancer Base No. 11. Lyon, France, International Agency for Research on Cancer, 2013.
- Dai T, Huang YY, Hamblin MR: Photodynamic therapy for localized infections—state of the art. *Photodiagnosis Photodyn Ther* 6(3-4): 170-188, 2009. DOI: 10.1016/j.pdpdt.2009.10.008
- Lima E, Reis LV: Photodynamic therapy: from the basics to the current progress of N-heterocyclic-bearing dyes as effective photosensitizers. *Molecules* 28(13): 5092, 2023. DOI: 10.3390/molecules28135092
- Bryden F, Boyle RW: Metalloporphyrins for Medical Imaging Applications. In: *Advances in Inorganic Chemistry*. van Eldik R, Hubbard CD (eds.). Amsterdam, the Netherlands, Elsevier, vol. 68, pp. 141-221, 2016.
- Buglak AA, Filatov MA, Hussain MA, Sugimoto M: Singlet oxygen generation by porphyrins and metalloporphyrins revisited: A quantitative structure-property relationship (QSPR) study. *J Photochem Photobiol A Chem* 403: 112833, 2020. DOI: 10.1016/j.jphotochem.2020.112833
- Tsolekile N, Nelana S, Oluwafemi OS: Porphyrin as diagnostic and therapeutic agent. *Molecules* 24(14): 2669, 2019. DOI: 10.3390/molecules24142669
- Lo PC, Rodríguez-Morgade MS, Pandey RK, Ng DKP, Torres T, Dumoulin F: The unique features and promises of phthalocyanines as advanced photosensitisers for photodynamic therapy of cancer. *Chem Soc Rev* 49: 1041-1056, 2020. DOI: 10.1039/c9cs00129h
- Sasaki M, Tanaka M, Kojima Y, Nomoto A, Shimmasu A, Narumi A, Yano S, Ozeki K, Shimura T, Kubota E, Kataoka H: Metal-conjugated maltotriose chlorins as novel photosensitizers for photodynamic therapy. *Anticancer Res* 44(3): 1011-1021, 2024. DOI: 10.21873/anticancer.16896
- Kubát P, Mosinger J: Photophysical properties of metal complexes of meso-tetrakis(4-sulphonatophenyl)porphyrin. *J Photochem Photobiol A* 96(1-3): 93-97, 1996. DOI: 10.1016/1010-6030(95)04279-2
- Griffiths J, Schofield J, Wainwright M, Brown SB: Some observations on the synthesis of polysubstituted zinc phthalocyanine sensitizers for photodynamic therapy. *Dyes Pigment* 33(1): 65-78, 1997. DOI: 10.1016/S0143-7208(96)00037-X
- Nyman ES, Hynninen PH: Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. *J Photochem Photobiol B* 73(1-2): 1-28, 2004. DOI: 10.1016/j.jphotobiol.2003.10.002
- Solban N, Rizvi I, Hasan T: Targeted photodynamic therapy. *Lasers Surg Med* 38(5): 522-531, 2006. DOI: 10.1002/lsm.20345
- Osterloh J, Vicente MGH: Mechanisms of porphyrinoid localization in tumors. *J. Porphyrins Phthalocyanines* 06(05): 305-324, 2002. DOI: 10.1142/S1088424602000373
- Yaroslavsky AN, Feng X, Muzikansky A, Hamblin MR: Fluorescence polarization of methylene blue as a quantitative marker of breast cancer at the cellular level. *Sci Rep* 9(1): 940, 2019. DOI: 10.1038/s41598-018-38265-0
- Jeena MT, Kim S, Jin S, Ryu JH: Recent progress in mitochondria-targeted drug and drug-free agents for cancer therapy. *Cancers (Basel)* 12(1): 4, 2019. DOI: 10.3390/cancers12010004
- Martins WK, Santos NF, Rocha CS, Bacellar IOL, Tsubone TM, Viotto AC, Matsukuma AY, Abrantes ABP, Siani P, Dias LG, Baptista MS: Parallel damage in mitochondria and lysosomes is an efficient way to photoinduce cell death. *Autophagy* 15(2): 259-279, 2019. DOI: 10.1080/15548627.2018.1515609
- Lim EJ, Oak CH, Heo J, Kim YH: Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells. *Oncol Rep* 30(2): 856-862, 2013. DOI: 10.3892/or.2013.2494
- Oliveira CS, Turchiello R, Kowaltowski AJ, Indig GL, Baptista MS: Major determinants of photoinduced cell death: Subcellular localization *versus* photosensitization efficiency. *Free Radic Biol*

- Med 51(4): 824-833, 2011. DOI: 10.1016/j.freeradbiomed.2011.05.023
- 20 Dos Santos AF, Terra LF, Wailemann RA, Oliveira TC, Gomes VM, Mineiro MF, Meotti FC, Bruni-Cardoso A, Baptista MS, Labriola L: Methylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cells. BMC Cancer 17(1): 194, 2017. DOI: 10.1186/s12885-017-3179-7
- 21 Acedo P, Stockert JC, Cañete M, Villanueva A: Two combined photosensitizers: a goal for more effective photodynamic therapy of cancer. Cell Death Dis 5(3): e1122, 2014. DOI: 10.1038/cddis.2014.77
- 22 McCormick BPP, Pansa MF, Sanabria LNM, Carvalho CMB, Faustino MAF, Neves MGPMs, Cavaleiro JAS, Vittar NBR, Rivarola VA: Cationic porphyrin derivatives for application in photodynamic therapy of cancer. Laser Phys 24(4): 045603, 2014. DOI: 10.1088/1054-660X/24/4/045603
- 23 Gamelas SRD, Moura NMM, Habraken Y, Piette J, Neves MGPMs, Faustino MAF: Tetracationic porphyrin derivatives against human breast cancer. J Photochem Photobiol B 222: 112258, 2021. DOI: 10.1016/j.jphotobiol.2021.112258
- 24 Žárská L, Malá Z, Langová K, Malina L, Binder S, Bajgar R, Kolářová H: The effect of two porphyrin photosensitizers TMPyP and ZnTPPS4 for application in photodynamic therapy of cancer cells *in vitro*. Photodiagnosis Photodyn Ther 34: 102224, 2021. DOI: 10.1016/j.pdpdt.2021.102224
- 25 Krestyn E, Kolarova H, Bajgar R, Tomankova K: Photodynamic properties of ZnTPPS4, ClAlPcS2 and ALA in human melanoma G361 cells. Toxicol In Vitro 24(1): 286-291, 2010. DOI: 10.1016/j.tiv.2009.08.015
- 26 Pola M, Kolarova H, Ruzicka J, Zholobenko A, Modriansky M, Mosinger J, Bajgar R: Effects of zinc porphyrin and zinc phthalocyanine derivatives in photodynamic anticancer therapy under different partial pressures of oxygen *in vitro*. Invest New Drugs 39(1): 89-97, 2021. DOI: 10.1007/s10637-020-00990-7

Received August 12, 2024

Revised September 2, 2024

Accepted September 3, 2024